Benefits
Cognitive Function (Mixed Evidence)
Older 1940s research showed pregnenolone improved cognitive performance in industrial workers. Modern trials less consistent. trial in schizophrenia patients showed cognitive improvements with high-dose pregnenolone (500 mg/day). Mechanism: neurosteroid effects.
Bipolar Disorder Adjunct (Research)
trial of pregnenolone (500 mg/day) in bipolar depression showed reduced depression and anxiety vs placebo. Generated continuing research interest. Specific clinical context, not general use.
Schizophrenia Cognitive Symptoms (Research)
Multiple trials showing high-dose pregnenolone may improve negative and cognitive symptoms in schizophrenia. Adjunct only.
Joint Pain / Arthritis (Older Research)
1940s-50s research showed pregnenolone reduced arthritis symptoms. Largely abandoned as cortisone-type anti-inflammatories developed. Limited modern research.
Theoretical Anti-Aging / Hormone Precursor Support
Used in some integrative anti-aging protocols based on age-related decline in pregnenolone and downstream hormones. INSUFFICIENT EVIDENCE for anti-aging claims; reasonable mechanism but clinical translation unclear.
Mechanism of action
Steroidogenic Pathway Precursor
Pregnenolone is the FIRST steroid hormone synthesized from cholesterol — by CYP11A1 (cholesterol side-chain cleavage enzyme). All other steroid hormones (progesterone, cortisol, aldosterone, DHEA, testosterone, estrogens) derive from pregnenolone. Supplementation increases substrate availability.
Direct Neurosteroid Activity
Pregnenolone (and pregnenolone sulfate) acts directly on GABA-A and NMDA receptors — neurosteroid effects independent of conversion to other hormones. May contribute to cognitive and mood effects.
Pregnenolone Sulfate (PS) Effects
Pregnenolone is sulfated in body to PS — a NEGATIVE allosteric modulator of GABA-A and POSITIVE modulator of NMDA receptors. PS has alerting/cognitive effects; pregnenolone itself has more variable effects.
Variable Downstream Hormone Production
Supplemental pregnenolone is converted to varying amounts of progesterone, cortisol, DHEA, testosterone, estrogens depending on individual enzymatic activity. Effects differ between individuals — explains variable clinical responses.
Clinical trials
RCT of pregnenolone (500 mg/day) vs placebo in 80 bipolar depression patients for 12 weeks.
80 bipolar depression patients.
Significant reduction in depression and anxiety scores vs placebo. Generated interest in pregnenolone for mood disorders. Adjunctive — not replacement for evidence-based bipolar treatment.
RCT of pregnenolone (up to 500 mg/day) vs placebo in 21 schizophrenia patients for 8 weeks.
21 schizophrenia patients.
Significant improvement in negative symptoms and cognitive function vs placebo. Adjunct to standard antipsychotic treatment. Subsequent trials have mixed results.